How to buy Sierra Oncology stock

Sierra Oncology, Inc is a biotechnology business based in the US. Sierra Oncology shares (SRRA) are listed on the NASDAQ and all prices are listed in US Dollars. Sierra Oncology employs 69 staff and has a trailing 12-month revenue of around 0.00.

Sierra Oncology share price

Use our graph to track the performance of SRRA stocks over time.

Sierra Oncology shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$10.02 - $20.43
50-day moving average	$17.46
200-day moving average	$15.23
Wall St. target price	$27.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.78

Buy Sierra Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Sierra Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sierra Oncology, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sierra Oncology financials

Revenue TTM	$300,000
Gross profit TTM	$-44,818,000
Return on assets TTM	-30.88%
Return on equity TTM	-87.79%
Profit margin	0%
Book value	$8.80
Market capitalisation	$203 million

TTM: trailing 12 months

Shorting Sierra Oncology shares

There are currently 24,232 Sierra Oncology shares held short by investors – that's known as Sierra Oncology's "short interest". This figure is 237% up from 7,191 last month.

There are a few different ways that this level of interest in shorting Sierra Oncology shares can be evaluated.

Sierra Oncology's "short interest ratio" (SIR)

Sierra Oncology's "short interest ratio" (SIR) is the quantity of Sierra Oncology shares currently shorted divided by the average quantity of Sierra Oncology shares traded daily (recently around 67311.111111111). Sierra Oncology's SIR currently stands at 0.36. In other words for every 100,000 Sierra Oncology shares traded daily on the market, roughly 360 shares are currently held short.

However Sierra Oncology's short interest can also be evaluated against the total number of Sierra Oncology shares, or, against the total number of tradable Sierra Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sierra Oncology's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sierra Oncology shares in existence, roughly 0 shares are currently held short) or 0.0055% of the tradable shares (for every 100,000 tradable Sierra Oncology shares, roughly 6 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sierra Oncology.

Find out more about how you can short Sierra Oncology stock.

Sierra Oncology share dividends

We're not expecting Sierra Oncology to pay a dividend over the next 12 months.

Have Sierra Oncology's shares ever split?

Sierra Oncology's shares were split on a 1:40 basis on 22 January 2020. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sierra Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Sierra Oncology shares which in turn could have impacted Sierra Oncology's share price.

Sierra Oncology share price volatility

Over the last 12 months, Sierra Oncology's shares have ranged in value from as little as $10.02 up to $20.43. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sierra Oncology's is 1.0778. This would suggest that Sierra Oncology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Sierra Oncology overview

Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017.

Frequently asked questions

• What percentage of Sierra Oncology is owned by insiders or institutions?

  Currently 6.352% of Sierra Oncology shares are held by insiders and 85.119% by institutions.

• How many people work for Sierra Oncology?

  Latest data suggests 69 work at Sierra Oncology.

• When does the fiscal year end for Sierra Oncology?

  Sierra Oncology's fiscal year ends in December.

• Where is Sierra Oncology based?

  Sierra Oncology's address is: 1820 Gateway Drive, San Mateo, CA, United States, 94404

• What is Sierra Oncology's ISIN number?

  Sierra Oncology's international securities identification number is: US82640U4040

• What is Sierra Oncology's CUSIP number?

  Sierra Oncology's Committee on Uniform Securities Identification Procedures number is: 74346L101